Pluristem (PSTI) Receives Approval to Commence PLX-PAD Phase II in Germany
- Weak earnings weigh on Wall Street; Fed awaited
- Netflix (NFLX) Director Jay Hoag Scoops Up 600,000 Shares
- Mobileye (MBLY) Falls as Tesla (TSLA) Relationship to Come to an End
- Oil dips on oversupply worries; U.S. crude hits April lows
- Snapchat Is Playing for Keeps, Which is Bad News for Facebook's (FB) Instagram
Pluristem Therapeutics, Inc. (Nasdaq: PSTI) announced that the Paul-Ehrlich-Institute (PEI), the medical regulatory body for biological medicinal products for the Federal Republic of Germany, has approved the company's request to initiate a Phase II study using PLX-PAD cells in patients suffering from Intermittent Claudication (IC). IC is a subset of Peripheral Artery Disease (PAD). According to The SAGE Group and HCUP 2007 Inpatient Data, the prevalence of IC in the United States is approximately 14 million patients, representing a cost of approximately $2.5 billion annually to the healthcare system.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Therapeutics (VKTX) Announces Top-Line Data from VK0214 PoC Study; Primary Objective Met
- Noodles & Company (NDLS) CEO Reddy to Resign; Offers Prelim. Q2 Results
- AbbVie's (ABBV) VIEKIRA XR NDA Approved by U.S. FDA
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!